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Seven Brazilian sites participating in the Pediatric AIDS Clinical Trials Group international cryopreser-
vation quality assurance pilot program cryopreserved and shipped peripheral blood mononuclear cells
(PBMC) to a central U.S. laboratory for analysis. Cell viability and recovery significantly increased over time.
A wet-laboratory training session conducted at the central laboratory significantly improved the quality of the
cryopreserved PBMC.
The utilization of cryopreserved peripheral blood mononu-
clear cells (PBMC) for immunologic assays has recently in-
creased. These cells are particularly useful in clinical trials with
low end-point frequencies, because they allow the performance
of assays after the complete identification of the end points (1,
8). Cryopreserved PBMC can be assayed in batches, avoiding
inter- and intralaboratory variabilities when they represent po-
tential confounders (6).
The use of cryopreserved PBMC in immunological assays
poses challenges, including the availability of adequate equip-
ment and the need for technical proficiency. Assays must be
adapted and validated for the use of cryopreserved PBMC, and
the quality of the frozen cells has to be monitored to ensure
reliable results in functional and phenotypic assays. We have
previously shown that the results of functional assays are
strictly dependent on the viability of the cryopreserved PBMC
(9), such that70% viability compromises lymphoproliferative
responses to antigens and mitogens. PBMC with viability of
70% are also suitable for cytokine production studies, flow
cytometric analyses, and immunomagnetic cell separation (4, 5,
7, 9). While cell recovery does not interfere with the results of
immunologic assays, the recovery of only a small proportion of
cells may preclude assay performance altogether. Based on
these observations, cryopreservation quality assurance (QA)
programs must monitor the viability and recovery of cryopre-
served PBMC. We report here on an effort to assess and
improve the ability of seven Pediatric AIDS Clinical Trials
Group (PACTG) sites in Brazil to cryopreserve viable PBMC.
This program included seven Brazilian sites, the Division of
AIDS Immunology QA (IQA) Program, and the PACTG
Cryopreservation Working Group. Pertinent aspects of this
study were approved by local institutional review boards and
the Brazilian National Research Council. The PACTG
cryopreservation consensus protocol (http://impaact.s-3.com
/immlab.htm) was distributed to the sites and discussed in
detail over conference calls. The first three QA rounds used
PBMC from 5 to 10 healthy volunteers per site. Cryopreserved
PBMC were stored in liquid nitrogen at the sites and shipped
to the IQA on dry ice. The time elapsed during transportation
and the amount of dry ice in the package upon arrival were
recorded by the IQA. At the IQA, thawed PBMC were as-
sessed for viability and recovery. Companion vials were also
thawed at the sites to evaluate the effects of shipment on
viability and recovery. Troubleshooting occurred with bi-
monthly conference calls. After the first three shipments, tech-
nologists from five sites participated in a wet-laboratory work-
shop at the IQA for hands-on training. After the workshop,
QA rounds included cells from human immunodeficiency virus
(HIV)-infected and uninfected volunteers. A second wet-lab-
oratory workshop was organized 1 year after the first one.
The viability of PBMC thawed according to the PACTG
cryopreservation consensus protocol was measured manually
by the trypan blue exclusion method. Statistical analysis (using
Prism 4 software; GraphPad) of 11 QA rounds showed a sig-
nificant increase over time of the cryopreserved PBMC viabil-
ity, from a mean  standard error of the mean of 61%  6%
to 88%  2% (P  0.0001; Fig. 1A). A significant increase in
viability occurred after the first wet-laboratory workshop but
not after the second one. The proportion of samples unsuitable
for functional assays due to viability 70% decreased from
50% of 10 samples in the first QA round to none of 14 samples
in the last round (Fig. 1B).
Recovery, defined as the number of viable thawed PBMC
over the original number of cryopreserved cells, also increased
over time, from 71%  5% to 91%  9% (P  0.0001; Fig. 2).
The first wet-laboratory workshop caused a significant increase
in recovery (P 0.006), but the second one did not (P 0.70).
Transportation time from Brazilian sites to the IQA was
48 h, with one exception when the package was held by U.S.
customs officials. None of the poor viability or recovery of
PBMC cryopreserved at the international sites could be as-
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cribed to shipment conditions, because viability and recovery
results were similar for paired cryopreserved samples thawed
at the IQA site versus those on-site. All but one of the first
shipments arrived at its destination with a satisfactory amount
of dry ice. The cost of shipment from international sites aver-
aged $350/package.
Our data indicate that a proactive approach to PBMC cryo-
preservation, including wet-laboratory training and systematic
conference call troubleshooting, was associated with fast and
robust improvement of the quality of the cryopreserved
PBMC. A cryopreservation QA program for U.S. ACTG sites
has been in existence since November of 2000. Compared with
the results obtained from U.S. sites (R. Louzao, personal com-
munication), the baseline cryopreserved PBMC viability at the
international sites was considerably lower, with an average of
77% versus 93%, respectively. However, the viability of the last
QA round analyzed for this study was comparable to the via-
bility registered for U.S. sites.
The single most important intervention that improved the
quality of the cryopreserved PBMC was the first wet-laboratory
workshop. The second workshop, which included different
technologists from the same sites, was not associated with
significant changes in the quality of the cryopreserved PBMC,
suggesting that hands-on training of a single representative per
laboratory may be sufficient to ensure that standardized pro-
cedures are adopted. The technical problems identified with
the conference calls were laboratory specific, suggesting that
individual counseling might be equally effective.
Sample shipment was satisfactory coming from international
sites, and it did not affect the results of the QA program.
However, international shipment was expensive, amounting to
an approximately 10-fold value of domestic shipments.
This report shows the value of QA programs with respect to
the quality of procedures, which is in accordance with that of
previous studies (2, 3). QA programs may vary with respect to
the degree of intervention, from a highly proactive approach,
such as the one described here, to a passive approach, whereby
samples are assessed and results are reported without requir-
ing corrective actions. Although a proactive approach has the
advantage of ensuring rapid and robust improvement of the
quality of the cryopreserved samples, it has disadvantages that
need to be weighed when designing a QA program. These
disadvantages include higher cost and the ability to accommo-
date a limited number of participants in activities such as
workshops and conference calls. The balance between the sci-
entific and financial losses associated with samples that are
poorly cryopreserved versus the higher cost of a proactive
cryopreservation QA program may determine the ultimate
choice of the approach.
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